問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
20022027
Total
5576
I
615
I/II
269
II
1305
II/III
138
III
2775
IV
109
363
林家齊
楊志新
葉士芃
顏家瑞
張基晟
夏德椿
白禮源
陳彩雲
楊宗穎
曾令民
吳尚殷
李日翔
廖斌志
何肇基
徐偉勛
廖唯昱
陳冠宇
余忠仁
許嘉林
National Taiwan University Hospital
Linkou Chang Gung Medical Foundation
Taipei Veterans General Hospital
China Medical University Hospital
Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.
Taichung Veterans General Hospital
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital
Tri-Service General Hospital
CHANGHUA CHRISTIAN HOSPITAL
下載
2019-11-01 - 2026-09-07
Condition/Disease
Test Drug
Participate Sites2Sites
Recruiting2Sites
2020-04-01 - 2026-05-01
Advanced Malignancies
BGB-A317 (Tislelizumab)和BGB-290 (Pamiparib)
Participate Sites9Sites
Not yet recruiting4Sites
Recruiting3Sites
Terminated2Sites
2017-10-31 - 2026-11-30
2021-10-01 - 2026-06-30
Participate Sites5Sites
Recruiting5Sites
2021-02-01 - 2026-03-31
Participate Sites10Sites
Not yet recruiting2Sites
Recruiting8Sites
全部
